Dr
Vivien
Verbrugge

Partner & Patent Attorney

Rennes Office

Engineering

Telephone. +33672866728
Mobile. +33672866728
Email. [email protected]
Vcard
Linkedin

Experience

Vivien’s wealth of experience as an in-house attorney, advising at Management and Board level within global companies in multiple jurisdictions, makes him well placed to advise in-house IP and Legal Counsel in relation to IP opportunities and threats for both SMEs and multinationals. Vivien regularly advises clients on portfolio creation, infringement avoidance and freedom to commercialise, portfolio enforcement and dispute resolution matters. Vivien has also advised on multi-jurisdiction portfolio acquisitions, secured successful outcomes in EPO oppositions and coordinated many IP litigations.

Specialisms

Industries

Services

Qualifications

Patent Attorney

European
French

MPHYS

Master in Physics & engineer degree

LLM

University of Strasbourg

PHD

Physics, Optoectronics and Telecom

OTHER

Vlerick management program

Conferences: 2022

May 31st 2022

Innovation & IP Forum and Awards 2022

Attended

Event details

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 19th May 2022

HGF Complete webinar: comparison of registered and unregistered design rights procedures before the EUIPO and UKIPO

HGF is hosting a series of HGF Complete webinars this Spring. Our expert speakers will discuss trade marks and designs in the EU and the UK. We will compare and …

Event details
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us